Clinical-stage biopharmaceutical developing LO2A, an ophthalmic drug for dry eye syndrome (DES), conjunctivochalasis (CCh) and Sjögren's patients. Licensed to commercialize LO2A, completed Phase II in CCh and conducting Phase IV in DES for Sjögren's, with intended distribution via local and multinational distributors.